What’s going on in the world of radiopharmaceuticals? Find out here.
News & Events
Check out the latest radiopharmaceutical news
News & Press Releases
Clarity and Nucleus RadioPharma sign Master Services Agreement and Cu-67 SAR-bisPSMA Clinical Supply Agreement
Nucleus RadioPharma has entered into a new agreement that will utilize their state-of-the-art facility located in Rochester, MN, to manufacture the 67Cu-SAR-bisPSMA drug product...
Read More
AstraZeneca-backed CDMO Nucleus RadioPharma to boost commercial capacity
As the radiopharma space heats up, CDMO Nucleus RadioPharma is expanding its commercial manufacturing with two new facilities to cater to potential clients outside North America. The CDMO has started…
Read More
Nucleus RadioPharma Expands Radiopharmaceutical Research, Development and Manufacturing Capacity, Addressing Nationwide Supply Chain Constraints
Nucleus RadioPharma today announced the development of two new facilities totaling over 100,000 square feet in Mesa, Arizona and Springhouse, Pennsylvania. These first-of-a-kind facilities will house research, development, and commercial…
Read More
Expanding Radiopharmaceuticals for Cancer Treatment: Addressing Supply and Manufacturing Challenges – Charles Conroy
Dr. Oliver Sartor interviews Chuck Conroy about Nucleus RadioPharma’s role in radiopharmaceutical manufacturing and distribution. Mr. Conroy explains that Nucleus RadioPharma aims to support both small and large pharmaceutical companies…
Read More
Nucleus RadioPharma CEO Chuck Conroy featured In C&EN article: Investment grows in radiopharma manufacturing
The rising interest in developing radiopharmaceuticals as cancer treatments is sparking increased investment in manufacturing these therapies.
Read More
Nucleus RadioPharma Secures Series A Extension Funding with AstraZeneca Investment
Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the closing of a Series A extension round with new investor AstraZeneca (LSE/STO/Nasdaq:…
Read More